300685.SZ
艾德生物
SZSE · Healthcare · C 制造业 · CN
CNY 18.41
−3.05%Sep 1, 2026, 09:29 UTC
Amoy Diagnostics announced that it has repurchased 9.1193 million shares for about 171 million yuan under its buyback program to cancel shares and reduce registered capital.
Source:Aug 24, 2026, 09:48 UTC
Amoy Diagnostics reported its first-half 2026 results: revenue of 559 million yuan, down 3.45% year-on-year; net profit attributable to shareholders of 166 million yuan, down 12.12% from 189 million yuan in the same period of 2025; non-recurring net profit of 162 million yuan, down 12.49%.
Source:Aug 17, 2026, 06:15 UTC
Japan's Ministry of Health, Labour and Welfare approved Amoy Diagnostics' AiHuiJie (PCR11) as a companion diagnostic for Zongheitinib (Saint-Hetu) in Japan on August 17, 2026.
Source:Aug 5, 2026, 07:41 UTC
Amoy Diagnostics and its second-level wholly-owned subsidiary recently obtained two invention patent certificates from the China National Intellectual Property Administration, with the patents already applied to related products.
Source:Aug 3, 2026, 12:39 UTC
On the evening of August 3, 2026, 31 STAR Market companies disclosed buyback or shareholding increase progress announcements, including 29 buyback progress updates and 2 shareholding increase updates.
Source:Jul 27, 2026, 01:51 UTC
Sinopharm Group acquired IVD leader Amoy Diagnostics for about 1.654 billion yuan.
Source: